CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma
Clinical trial NCT05052567 · COMPLETED
Trial details
- NCT number
- NCT05052567
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-21
- Primary completion
- 2024-06-29
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.